Trial Profile
A Phase 1/2a Single Dose and 28-day Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream 0.5% and 0.15% in Adults With Mild to Moderate Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Arcutis Biotherapeutics
- 24 Nov 2022 Results assessing the pharmacokinetic profile of roflumilast delivered topically from a phase I maximal usage study and data from phase II and phase III studies (NCT04279119, NCT03392168, NCT04211363, NCT04211389), published in the American Journal of Clinical Dermatology.
- 03 Aug 2020 Primary endpoint (4 Week TPSS x TPA) has been met, according to an an Arcutis Biotherapeutics Media Release.
- 03 Aug 2020 Accoording to an Arcutis Biotherapeutics Media Release, results from this trial were published in an article in the August 2020 issue of The Journal of Drugs in Dermatology.